Heart failure & cardiomyopathies
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Authors' conclusion
Cognitive change, measured by MMSE, did not differ between treatment with sacubitril/valsartan and treatment with valsartan in patients with heart failure with preserved ejection fraction.
Study context
- Population
- Patients with HFpEF in the PARAGON-HF Mini-Mental State Examination (MMSE) substudy (mean age 73 years)median follow-up 32 months
- Participants
- 2,895 patients
- Comparison
- Sacubitril/valsartan vs valsartan
- Sacubitril/valsartann = 1,453
- Valsartann = 1,442reference
- Primary endpoint
- Change from baseline in MMSE score
- Follow-up
- 96 weeks
Methodological detailsprespecified substudy
- Prespecified substudy
Primary result
As reported in the abstract
Sacubitril/valsartan
−0.05
mean change · SE 0.07
Valsartan
−0.04
mean change · SE 0.07
Further findings
≥3-point MMSE decline, decrease to MMSE <24, and combinations (post hoc)
- No difference between sacubitril/valsartan and valsartan
- Post hoc
Cognitive change in subgroup tested for APOE ε4 genotype
- No difference
Safety
Dementia-related adverse events
- No difference between sacubitril/valsartan and valsartan
- Post hoc
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF. Circulation. Published 6 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →